Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

43:40
 
Share
 

Manage episode 513647780 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Laura Huppert, including the following topics:

  • General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00)
  • Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44)
  • Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30)
  • Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13)
  • Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25)
  • CNS penetration and activity of ADCs in the treatment of breast cancer (22:27)
  • Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24)
  • Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05)
  • Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51)
  • Ongoing evaluation of ADCs in the localized disease setting (35:42)
  • Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38)

CME information and select publications

  continue reading

858 episodes

Artwork
iconShare
 
Manage episode 513647780 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Laura Huppert, including the following topics:

  • General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00)
  • Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44)
  • Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30)
  • Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13)
  • Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25)
  • CNS penetration and activity of ADCs in the treatment of breast cancer (22:27)
  • Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24)
  • Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05)
  • Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51)
  • Ongoing evaluation of ADCs in the localized disease setting (35:42)
  • Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38)

CME information and select publications

  continue reading

858 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play